Association of prostate cancer with rapid N-acetyltransferase 1 (NAT1*10) in Combination with slow N-acetyltransferase 2 acetylator genotypes in a pilot case-control study

Environmental and Molecular Mutagenesis

Volumn 40, Issue 3, 2002, Pages 161-167

  Hein, David W ^a   Leff, Matthew A ^a   Ishibe, Naoko ^b   Sinha, Rashmi ^b   Frazier, Harold A ^c   Doll, Mark A ^a   Xiao, Gong H ^a   Weinrich, Martin C ^a   Caporaso, Neil E ^b  

^a University of Louisville School of Medicine   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c WALTER REED ARMY MEDICAL CENTER   (United States)

Author keywords

Acetylator genotype; N acetyltransferase 1; N acetyltransferase 2; Prostate cancer

Indexed keywords

ACYLTRANSFERASE; N ACYLTRANSFERASE 1; N ACYLTRANSFERASE 2; UNCLASSIFIED DRUG;

ADULT; AGE; AGED; ARTICLE; CANCER INCIDENCE; CANCER RISK; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DNA POLYMORPHISM; ETHNIC GROUP; GENOTYPE; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT REFERRAL; PILOT STUDY; PROSTATE CANCER; RACE;

AGED; ALLELES; ARYLAMINE N-ACETYLTRANSFERASE; CASE-CONTROL STUDIES; GENOTYPE; HUMANS; ISOENZYMES; MALE; MIDDLE AGED; ODDS RATIO; PILOT PROJECTS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATIC NEOPLASMS;

EID: 0036391671     PISSN: 08936692     EISSN: None     Source Type: Journal    
DOI: 10.1002/em.10103     Document Type: Article

References (69)

1. Agundez JA, Martinez C, Olivera M, Gallardo L, Ladero JM, Rosad C, Prados J, Rodriguez-Molina J, Resel L, Benitez J. 1998. Expression in human prostate of drug-and carcinogen-metabolizing enzymes: association with prostate cancer risk. Br J Cancer 78:1361-1367.
2. Archer L, Morse P, Jones RF, Shirai T. Haas GP, Wang CY. 2000 Carcinogenicity of the N-hydroxy derivative of 2-amino-1-methyl-6-phenylimidazo[4,5-h]pyridine, 2-amino-3,8-dimethylimidazo[4,5-f]-quinoxaline and 3,2′-dimethyl-4-aminobiphenyl in the rat. Cancer Lett 155:55-60.
3. Badawi AF, Hirvonen A, Bell DA, Lang NP, Kadlubar FF, 1995. Role of aromatic amine acetyltransferases, NAT1 and NAT2, in carcinogen-DNA adduct formation in the urinary bladder. Cancer Res 55:5230-5237.
4. Bell DA, Badawi AF, Lang NP, Ilett KF, Kadlubar F, Hirvonen A. 1995a. Polyrnorphism in the NAT1 polyadenylation signal: association of NAT1*10 allele with higher N-acetylation activity in bladder and colon tissue samples. Cancer Res 55:5226-5229.
5. Bell DA, Stephens E, Castranio T, Umbach DM, Watson M, Deakin M, Elder J, Duncan H, Hendrickse C, Strange RC. 1995b. Polyadenylation polymorphism in the N-acetyltransferase gene 1 (NAT1) increases risk for colorectal cancer. Cancer Res 55:3537-3542.
6. Bogen KT, Keating GA. 2001. U.S. dietary exposures to heterocyclic amines. J Expo Anal Environ Epidemiol 11:155-168.
7. Boissy RJ, Watson MA, Umbach DM, Deakin M, Elder J, Strange RC, Bell DA. 2000. A pilot study investigating the role of NAT1 and NAT2 polymorphisms in gastric adenocarcinoma. Int J Cancer 87:507-511.
8. Brockmoller J, Cascorbi I, Kerb R, Roots I. 1996. Combined analysis of inherited polymorphisms in arylamine N-acetyltransferase 2, glutathione S-transferases M1 and T1, microsomal epoxide hydrolase, and cytochrome P450 enzymes as modulators of bladder cancer risk. Cancer Res 56:3915-3925.
9. Brockton N, Little J, Sharp L, Cotton SC. 2000. N-acetyltransferase polymorphisms and colorectal cancer: a HuGE review. Am J Epidemiol 151:846-861.
10. Butcher NJ, Ilett KF, Minchin RF. 1998. Functional polymorphism of the human arylamine N-acetyltransferase type 1 gene caused by C190T and G590A mutations. Pharmacogenetics 8:67-72.
11. Butler WJ, Ryan P, Roberts-Thomson IC. 2001. Metabolic genotypes and risk for colorectal cancer. J Gastroenterol Hepatol 16:631-635.
12. Cartwright RA, Glashan RW, Rogers HJ, Ahmad RA, Barham-Hall D, Higgens E, Kahn M. 1982. A role of N-acetyltransferase phenotypes in bladder carcinogenesis: a pharmacogenetic epidemiological approach to bladder cancer. Lancet 2:842-846.
13. Cascorbi I, Roots I, Brockmoller J. 2001. Association of NAT1 and NAT2 polymorphisms to urinary bladder cancer: significantly reduced risk in subjects with NAT1*10. Cancer Res 61:5051-5056.
14. Chen J, Stampfer MJ, Hough HL, Garcia-Closas M, Willet WC, Hennekens, CH, Kelsey KT, Hunter D. 1998. A prospective study of N-acetyltransferase genotype, red meat intake, and risk of colorectal cancer. Cancer Res 58:3307-3311.
15. Cui L, Takahashi S, Tada M, Kato K, Yamada Y, Kohri K, Shirai T. 2000. Immunohistochemical detection of carcinogen-DNA adducts in normal human prostate tissues transplanted into the subcutis of athymic nude mice: results with 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) and 3,2′-dimethyl-4-aminobiphenyl (DMAB) and relation to cytochrome P450s and N-acetyltransferase activity. Jpn J Cancer Res 91:52-58.
16. Deitz AC, Zheng W, Leff MA, Gross M, Wen W-Q, Doll MA, Xiao GH, Folsom AR, Hein DW. 2000. N-acetyltransferase-2 genetic polymorphism, well-done meat intake, and breast cancer risk among postmenopausal women. Cancer Epidemiol Biomark Prev 9:905-910.
17. Doll MA, Hein DW. 2001. Comprehensive human NAT2 genotype method using single nucleotide polymorphism-specific polymerase chain reaction primers and fluorogenic probes. Anal Biochem 288:106-108.
18. Doll MA, Hein DW. 2002. Rapid genotype method to distinguish frequent and/or functional polymorphisms in human N-acetyltransferase-1 (NAT1). Anal Biochem 301:328-332.
19. Filiadis IF, Georgiou I, Alamanos Y, Kranas V, Giannakopoulos X, Lolis D. 1999 Genotypes of N-acetyltransferase-2 and risk of bladder cancer: a case-control study. J Urol 161:1672-1675.
20. Fretland AJ, Doll MA, Leff MA, Hein DW. 2001a. Functional characterization of nucleotide polymorphisms in the coding region of human N-acetyltransferase 1. Pharmacogenetics 11:511-520.
21. Fretland AJ, Leff MA, Doll MA, Hein DW. 2001b. Functional characterization of human N-acetyltransferase 2 (NAT2) single nucleotide polymorphisms. Pharmacogenetics 11:207-215.
22. Fretland AJ, Doll MA, Zhu Y, Smith L, Leff MA, Hein DW. 2002. Effect of nucleic acid substitutions in N-acetyltransferase-1 on N-acetylation (deactivation) and O-acetylation (activation) of arylamine carcinogens: implications for cancer predisposition. Cancer Detect Prev 26:10-14.
23. Fronhoffs S, Bruning T, Ortiz-Pallardo E, Brode P, Loch B, Harth V, Sachinidis, A, Bolt HM, Herberhold C, Vetter H, Ko, Y. 2001. Real-time PCR analysis of the N-acetyltransferase NAT1 allele *3, *4, *10, *11, *14, and *17 polymorphisms in squamous cell cancer of head and neck. Carcinogenesis 22:1405-1412.
24. Fukutome K, Watanabe M, Shiraishi T, Murata M, Uemura H, Kubota Y, Kawamura J, Ito H, Yatani R. 1999. N-acetyltransferase 1 genetic polymorphism influences the risk of prostate cancer development. Cancer Lett 136:83-87.
25. Hein DW. 2002. Molecular genetics and function of NAT1 and NAT2: Role in aromatic amine metabolism and carcinogenesis. Mutat Res 506-507:65-77.
26. Hein DW, Doll MA, Rustan TD, Gray K, Feng Y, Ferguson RJ, Grant DM. 1993. Metabolic activation and deactivation of arylamine carcinogens by recombinant human NAT1 and polymorphic NAT2 acetyltransferases. Carcinogenesis 14:1633-1638.
27. Hein DW, Doll MA, Rustan TD, Ferguson RJ. 1995. Metabolic activation of N-hydroxyarylamines and N-hydroxyarylamides by 16 recombinant human NAT2 allozymes: effects of 7 specific NAT2 nucleic acid substitutions. Cancer Res 55:3531-3536.
28. Hein DW, Doll MA, Fretland AJ, Leff MA, Webb SJ, Xiao GH, Devanaboyina U-S, Nangju NA, Feng Y. 2000a. Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms. Cancer Epidemiol Biomark Prev 9:29-42.
29. Hein DW, McQueen CA, Grant DM, Goodfellow GH, Kadlubar FF, Weber WW. 2000b. Pharmacogenetics of the arylamine N-acetyltransferases: a symposium in honor of Wendell W. Weber. Drug Metab Dispos 28:1425-1432.
30. Henning S, Cascorbi I, Munchow B, Jahnke V, Roots I. 1999. Association of arylamine N-acetyltransferases NAT1 and NAT2 genotypes to laryngeal cancer risk. Pharmacogenetics 9:103-111.
31. Houston RS, Tomlinson IP. 2001. Polymorphisms and colorectal tumor risk. Gastroenterology 121:282-301.
32. Hsing AW, McLaughlin JK, Hrubec A, Blot WJ, Fraumeni FJ Jr. 1991. Tobacco use and prostate cancer: 26-year follow-up of US veterans. Am J Epidemiol 133:437-441.
33. Ishibe N, Sinha R, Hein DW, Kulldorff M, Strickland P, Fretland AJ, Chow W-H, Kadlubar FF, Lang NP, Rothman N. 2002. Genetic polymorphisms in heterocyclic amine metabolism and risk of colorectal adenomas. Pharmacogenetics 12:145-150.
34. Ito N, Shirai T, Tagawa Y, Nagamura A, Fukushima S. 1988. Variation in tumor yield in the prostate and other target organs of the rat in response to varied dosage and duration of administration of 3,2-dimethyl-4-aminobiphenyl. Cancer Res 48:4629-4632.
35. Katayama S, Fiala E, Reddy BS, Rivenson A, Silverman J, Williams GM, Weisburger JH. 1982. Prostate adenocarcinoma in rats: Induction by 3,2-dimethyl-4-aminobiphenyl. J Natl Cancer Inst 68:867-873.
36. Katoh T, Kaneko S, Boissy R, Watson M, Ikemura K, Bell DA. 1998. A pilot study testing the association between N-acetyltransferases 1 and 2 and risk of oral squamous cell carcinoma in Japanese people. Carcinogenesis 19:1803-1807.
37. Katoh T, Inatomi H, Yang M, Kawamato T, Matsumota T, Bell DA. 1999. Arylamine N-acetyltransferase 1 (NAT1) and 2 (NAT2) genes and risk of urothelial transitional cell carcinoma among Japanese. Pharmacogenetics 9:401-404.
38. Katoh T, Boissy R, Nagata N, Kitagawa K, Kuroda Y, Itoh H, Kawamoto T, Bell DA. 2000. Inherited polymorphism in the N-acetyltransferase 1 (NAT1) and 2 (NAT2) genes and susceptibility to gastric and colorectal adenocarcinoma. Int J Cancer 85:46-49.
39. Krajinovic M, Richer C, Sinnett H, Labuda D, Sinnett D. 2000. Genetic polymorphisms of N-acetyltransferases 1 and 2 and gene-gene interaction in the susceptibility to childhood acute lymphoblastic leukemia. Cancer Epidemiol Biomark Prev 9:557-562.
40. Krajinovic M, Ghadirian P, Richer C, Sinnett H, Gandini S, Perret C, Lacroix A, Labuda D, Sinnett D. 2001. Genetic susceptibility to breast cancer in French-Canadians: role of carcinogen-metabolizing enzymes and gene-environment interactions. Int J Cancer 92:220-225.
41. Lawson T, Kolar C. 2002. Human prostate epithelial cells metabolize chemicals of dietary origin to mutagens. Cancer Lett 175:141-146.
42. Layton DW, Bogen KT, Knize MG, Hatch FT, Johnson VM, Felton JS. 1995. Cancer risk of heterocyclic amines in cooked foods: an analysis and implications for research. Carcinogenesis 16:39-52.
43. Lin HJ, Probst-Hensch NM, Hughes NC, Sakamoto GT, Louis AD, Kau JH, Lin BK, Lee DB, Lin J, Frankl HD, Lee ER, Hardy S, Grant DM, Haile RW. 1998. Variants of N-acetyltransferase NAT1 and a case-control study of colorectal adenomas. Pharmacogenetics 8:269-281.
44. Manabe S, Tohyama K, Wada O, Aramaki T. 1991. Detection of a carcinogen, 2-amino-1-methyl-6-imidazo[4,5-b]pyridine (PHIP) in cigarette smoke condensate. Carcinogenesis 12:1945-1947.
45. Marcus PM, Hayes RB, Vineis P, Garcia-Closas M, Caporaso NE, Autrup H, Branch RA, Brockmoller J, Ishizaki T, Karakaya AE, Ladero JM, Mommsen S, Okkels H, Romkes M, Roots I, Rothman N. 2000. Cigarette smoking, N-acetyltransferase 2 acetylation status, and bladder cancer risk: a case-series meta-analysis of a gene-environment interaction. Cancer Epidemiol Biomarker Prev 9:461-467.
46. Mettlin C. 1997. Recent developments in the epidemiology of prostate cancer. Eur J Cancer Prev 33:340-347.
47. Millikan RC, Pittman GS, Newman B, Tse C-K, Selmin O, Rockhill B, Savitz D, Moorman PG, Bell DA. 1997. Cigarette smoking, N-acetyltransferases 1 and 2 and breast cancer risk. Carcinogenesis 18:2127-2132.
48. Norrish AE, Ferguson LR, Knize MG, Felton JS, Sharpe SJ, Jackson RT. 1999. Heterocyclic amine content of cooked meat and risk of prostate cancer. J Natl Cancer Inst 91:2038-2044.
49. Okkels H, Sigsgaard T, Wolf H, Autrup H. 1997. Arylamine N-acetyltransferase 1 (NAT1) and 2 (NAT2) polymorphisms in susceptibility to bladder cancer: the influence of smoking. Cancer Epidemiol Biomarker Prev 6:225-231.
50. Olshan AF, Weissler MC, Watson MA, Bell DA. 2000. GSTM1, GSTT1, GSTP1, CYP1A1 and NAT1 polymorphisms, tobacco use, and the risk of head and neck cancer. Cancer Epidemiol Biomark Prev 9:185-191.
51. O'Neil WM, Drobitch RK, MacArthur RD, Farrough MF, Doll MA, Fretland AJ, Hein DW, Crane LR, Svensson CR. 2000. Acetylator phenotype and genotype in patients infected with HIV: discordance between methods for phenotype determination and genotype. Pharmacogenetics 10:171-182.
52. 32P postlabelling analysis of urinary mutagens from smokers of black tobacco implicates 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) as a major DNA-damaging agent. Carcinogenesis 12:713-717.
53. Risch A, Wallace DM, Bathers S, Sim E. 1995. Slow N-acetylation genotype is a susceptibility factor in occupational and smoking related bladder cancer. Hum Mol Genet 4:231-236.
54. Sharpe CR, Siemiatycki J. 2001. Joint effects of smoking and body mass index on prostate cancer risk. Epidemiology 12:546-551.
55. Shirai T, Nakamura A, Fukushima S, Yamamoto A, Tada M, Ito N. 1990. Different carcinogenic responses in a variety of organs, including the prostate, of five different rats strains given 3,2′-dimethyl-4-aminobiphenyl. Carcinogenesis 11:793-797.
56. Shirai T, Iwaski S, Naito H, Masui T, Kato T, Imaida K. 1992. Dose dependence of N-hydroxy-3,2′-dimethyl-4-aminobiphenyl-induced rat prostate carcinogenesis. Jpn J Cancer Res 83:695-698.
57. Shirai T, Sano M, Tamano S, Takahasi S, Hirose M, Futauchi M, Hasegawa R, Imaida K, Matsumoto K, Wakabayashi K, Sugimura T, Ito N. 1997. The prostate: a target for carcinogenicity of 2-amino-1-methyl-6-phenylimidazo[4-5,b]pyridine (PhIP) derived from cooked foods. Cancer Res 57:195-198.
58. Shirai T, Cui L, Takahashi S, Futakuchi M, Asamoto M, Kato R, Ito N. 1999. Carcinogenicity of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) in the rat prostate and induction of invasive carcinomas by subsequent treatment with testosterone propionate. Cancer Lett 143:217-221.
59. Smelt VA, Mardon HJ, Sim E. 1998. Placental expression of arylamine N-acetyltransferases: evidence for linkage disequilibrium between NAT1*10 and NAT2*4 alleles of the two human N-acetyltransferase loci NAT1 and NAT2. Pharmacol Toxicol 83:149-157.
60. Taylor JA, Umbach DM, Stephens E, Castranio T, Paulson D, Roberson C, Johler, JL, Bell DA. 1998. The role of N-acetylation polymorphisms in smoking-associated bladder cancer: evidence of a genegene exposure three-way interaction. Cancer Res 58:3603-3610.
61. Varzim G, Monteiro E, Silva R, Pinheiro C, Lopes C. 2002. Polymorphisms of the arylamine N-acetyltransferase (NAT1 and NAT2) and larynx cancer susceptibility. J Otorhinolaryngol Relat Spec 64:206-212.
62. Vaziri SA, Hughes NC, Sampson H, Darlington G, Jewett MA, Grant DM. 2001. Variation in enzymes of arylamine procarcinogen biotrans-formation among bladder cancer patients and control subjects. Pharmacogenetics 11:7-20.
63. Wadelius M, Autrup JL, Stubbins MJ, Andersson S-O, Johansson J-E, Wadelius C, Wolf CR, Autrup H, Rane A. 1999. Polymorphisms in NAT2, CYP2D6, CYP2C19, and GSTP1 and their association with prostate cancer. Pharmacogenetics 9:333-340.
64. Wang CY, Debiec-Rychter M, Schut HA, Morse P, Jones RJ, Archer C, King CM, Haas GP. 1999. N-acetyltransferase expression and DNA binding of N-hydroxyheterocyclic amines in human prostate epithelium. Carcinogenesis 20:1591-1595.
65. Wikman H, Thiel S, Jager B, Schmezer P, Spiegelhalder B, Edler L, Dienemann H, Kayser K, Schulta V, Drings P, Bartsch H, Risch A. 2001. Relevance of N-acetyltransferase 1 and 2 (NAT1, NAT2) genetic polymorphisms in non-small cell lung cancer susceptibility. Pharmacogenetics 11:157-168.
66. Williams JA, Martin FL, Muir GH, Hewer A, Grover PL, Phillips DH. 2000. Metabolic activation of carcinogens and expression of various cytochromes P450 in human prostate tissue. Carcinogenesis 21:1683-1689.
67. Yeh CC, Chung JG, Wu HC, Li YC, Lee M, Hung CF. 2000. Effects of butylated hydroxyanisole and butylated hydrpxytoluene on DNA adduct formation and arylamines N-acetyltransferase activity in PC-3 cells (human prostate tumor) in vitro. Food Chem Toxicol 38:977-983.
68. Yeh CC, Hung CF, Wang WL, Chung JG. 2001. Kinetics of acetyl coenzyme A: arylamine N-acetyltransferase from rapid and slow acetylator human benign prostatic hyperplasia tissues. Urol Res 29:311-316.
69. Yu MW, Pai CI, Yang SY, Hsiao TJ, Chang HC, Lin SM, Liaw YF, Chen PJ, Chen CJ. 2000. Role of N-acetyltransferase polymorphisms in hepatitis B related hepatocellular carcinoma: impact of smoking on risk. Gut 47:703-709.